Physician profile
David A Sisam
NPI 1124194840
$13,454.94
in general payments reported to CMS, 2019-2025
34 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,886 · 2020: $1,327 · 2021: $1,095 · 2022: $1,402 · 2023: $1,075 · 2024: $567 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $6,065.50 | 2019-2023 | Steglatro |
| Novo Nordisk INC | $1,220.74 | 2019-2025 | Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $1,079.85 | 2019-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $986.36 | 2019-2024 | Cycloset |
| Abbvie INC. | $571.70 | 2019-2025 | Synthroid |
| Ibsa Pharma INC. | $407.46 | 2019-2024 | Tirosint, Tirosint, Licart |
| Astrazeneca Pharmaceuticals LP | $387.40 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $365.38 | 2021-2025 | |
| Antares Pharma, INC. | $344.64 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.38 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $228.30 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $207.96 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $207.71 | 2019-2022 | |
| Amgen INC. | $202.24 | 2024-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $200.84 | 2019-2023 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $96.76 | 2023 | |
| Corcept Therapeutics | $73.80 | 2019-2025 | Korlym |
| Dexcom, INC. | $64.88 | 2019-2024 | Dexcom G6 Transmitter |
| Soleno Therapeutics, INC. | $55.67 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $47.97 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $41.84 | 2022 | |
| Ascendis Pharma Endocrinology INC | $34.37 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $31.47 | 2024-2025 | NP Thyroid 60 |
| Clarus Therapeutics INC. | $30.78 | 2021 | |
| Kyowa Kirin, INC. | $28.65 | 2025 | |
| Nevro Corp. | $24.04 | 2024 | Senza |
| Madrigal Pharmaceuticals | $22.84 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $22.79 | 2025 | |
| Tolmar, INC. | $21.95 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.13 | 2020 | |
| Currax Pharmaceuticals LLC | $17.21 | 2025 | Contrave |
| Insulet Corporation | $16.26 | 2019 | |
| Acerus Pharmaceuticals Corporation | $14.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sisam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.